Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCRX Biocryst Pharmaceuticals

Market Closed 06-26 16:00:00 EDT

9.94

+0.04

+0.40%

盘后9.95

+0.01+0.10%

19:53 EDT

High10.19	Low9.66	Vol10.98M
Open9.91	D1 Closing9.90	Amplitude5.29%
Mkt Cap2.53B	Tradable Cap2.20B	Total Shares254.11M
T/O109.48M	T/O Rate4.97%	Tradable Shares221.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCRX","market":"US","secType":"STK","nameCN":"Biocryst Pharmaceuticals","latestPrice":9.94,"timestamp":1782504000000,"preClose":9.9,"halted":0,"volume":10980376,"hourTrading":{"tag":"盘后","latestPrice":9.95,"preClose":9.94,"latestTime":"19:53 EDT","volume":1121112,"amount":11143330.028101,"timestamp":1782518033197,"change":0.01,"changeRate":0.001006,"amplitude":0.034205},"delay":0,"changeRate":0.0040404040404039545,"floatShares":221000000,"shares":254105895,"eps":-1.771,"marketStatus":"Market Closed","change":0.04,"latestTime":"06-26 16:00:00 EDT","open":9.91,"high":10.185,"low":9.6613,"amount":109481167.53349599,"amplitude":0.052899,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.771,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":762670800000,"exchange":"NASDAQ","adjPreClose":9.9,"preHourTrading":{"tag":"盘前","latestPrice":9.91,"preClose":9.9,"latestTime":"09:29 EDT","volume":10310,"amount":101679.68409000001,"timestamp":1782480599999,"change":0.01,"changeRate":0.00101,"amplitude":0.032687},"postHourTrading":{"tag":"盘后","latestPrice":9.95,"preClose":9.94,"latestTime":"19:53 EDT","volume":1121112,"amount":11143330.028101,"timestamp":1782518033197,"change":0.01,"changeRate":0.001006,"amplitude":0.034205},"volumeRatio":1.120793700364577,"impliedVol":0.8882,"impliedVolPercentile":0.9243},"requestUrl":"/m/hq/s/BCRX/tweets","defaultTab":"tweets","newsList":[{"id":"2643229941","title":"How Investors Are Reacting To BioCryst (BCRX) Expanding Its HAE Prophylaxis Data Across Patient Groups","url":"https://stock-news.laohu8.com/highlight/detail?id=2643229941","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643229941?lang=en_us&edition=fundamental","pubTime":"2026-06-15 10:12","pubTimestamp":1781489538,"startTime":"0","endTime":"0","summary":"Earlier this week, BioCryst Pharmaceuticals reported new clinical trial and real-world data for its oral HAE prophylaxis ORLADEYO and investigational antibody navenibart, presented across multiple posters at the EAACI 2026 meeting in Istanbul.\nThe breadth of data, with sustained pediatric outcomes for ORLADEYO and subgroup consistency for navenibart, highlights how BioCryst is trying to extend HAE prophylaxis across age ranges and patient profiles.\nNext, we’ll examine how these broader,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-investors-are-reacting-to-biocryst-bcrx-expanding-its-ha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-investors-are-reacting-to-biocryst-bcrx-expanding-its-ha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","IE00B64QTZ34.USD","IE00B19Z6F94.USD","LU1169589451.USD","BK4211","LU1169590202.USD","ISBC","LU0012050646.USD","IE00BLDYK493.USD","LU0205194284.USD","LU0106261612.USD","LU0205193047.USD","BK4547","HAE","IE0034390439.USD","BCRX","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643218880","title":"BioCryst shareholders approve amended stock incentive plan, add 7 million shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2643218880","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643218880?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:11","pubTimestamp":1781295103,"startTime":"0","endTime":"0","summary":"BioCryst held its annual shareholder meeting on June 11, 2026.Shareholders ratified Ernst & Young as independent registered public accountants for 2026.Investors backed an amended and restated Stock Incentive Plan, expanding the share pool by 7 million shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL1s4hfG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642260401","title":"BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2642260401","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642260401?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:55","pubTimestamp":1781265347,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals'  Orladeyo was associated with \"early and sustained reductions\" in hereditary angioedema or HAE attacks, demonstrated by new clinical data from the ongoing APeX-P study, the company said Friday.Updated analysis of 48-week data from the study showed that Orladeyo treatment reduced HAE attack rates that require on-demand treatment and attacks that require professional care, without significant safety concerns, BioCryst said. The study assessed patients aged 2 to less than 12 years old.BioCryst also reported new data from its phase 1b/2 study of navenibart in HAE, demonstrating reductions in overall HAE attack rate. The analysis supports the ongoing phase 3 trial of navenibart as a potential long-acting therapy for the broad HAE patient population, the company added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4547","BK4139","BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642321267","title":"BioCryst says post hoc ALPHA-STAR analysis shows navenibart cuts HAE attack rates across patient subgroups","url":"https://stock-news.laohu8.com/highlight/detail?id=2642321267","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642321267?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:00","pubTimestamp":1781262059,"startTime":"0","endTime":"0","summary":"BioCryst disclosed new clinical data for ORLADEYO, with posters scheduled for presentation at the EAACI meeting in Istanbul on June 12-15.A long-term pediatric study showed sustained reductions in hereditary angioedema attacks needing rescue medication or professional care, with no new safety signals.A post hoc analysis of the early-stage ALPHA-STAR trial found investigational navenibart cut attack burden across patient subgroups, supporting its ongoing Phase 3 program.Separate real-world analyses set for EAACI pointed to fewer attacks, lower healthcare use, and strong patient satisfaction for ORLADEYO, including patients switching from other prophylaxis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL4V9lCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","SG9999014039.USD","NDAQ","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014005.SGD","BK4112","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","LU0314104364.USD","IE00B64PRP62.GBP","LU2095319765.USD","BCRX","BK4585","BK4139","IE00BN0W2V16.EUR","SG9999014021.USD","BK4588","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642673302","title":"BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of Hae Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642673302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642673302?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:00","pubTimestamp":1781262021,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42K0DY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4139","BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642492051","title":"BioCryst grants 9 new hires options for 33,950 shares, RSUs for 80,650 shares under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2642492051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642492051?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:05","pubTimestamp":1781035522,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals granted inducement equity awards to nine newly hired employees, covering 33,950 stock options and 80,650 RSUs.Options were struck at $8.57 per share, matching the June 1 closing price; each option carries a 10-year term.Awards vest in four equal annual installments starting on the first anniversary of the grant date, contingent on continued service.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL4GZWPR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","BK4139","BK4112","NDAQ","SG9999014039.USD","IE00BGHQF748.EUR","BCRX","LU2095319765.USD","LU2210149790.SGD","BK4547","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4585","IE00BN0W2W23.USD","LU2210150020.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642713492","title":"BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642713492","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642713492?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:05","pubTimestamp":1781035500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUAC8N8VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4139","BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638041715","title":"BioCryst presents new ORLADEYO, navenibart hereditary angioedema trial data at EAACI 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638041715","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638041715?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:03","pubTimestamp":1779879807,"startTime":"0","endTime":"0","summary":"BioCryst flagged new hereditary angioedema data for ORLADEYO and investigational navenibart at the EAACI meeting in Istanbul, June 12-15, 2026.Results will be presented in the future through seven abstracts spanning clinical-trial findings, real-world outcomes, and switching experience from other preventive therapies.ORLADEYO reports focus on fewer attacks, reduced need for rescue treatment or professional care, and lower healthcare resource use across adult, adolescent, and pediatric patients.Navenibart data from the ALPHA-STAR trial highlight clinical outcomes across patient subgroups, supporting its positioning as a long-acting preventive option.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL9GrLP5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4547","SG9999014021.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014013.SGD","NDAQ","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","BK4585","SG9999014039.USD","IE00BKPKM429.USD","LU2210149790.SGD","BCRX","LU2210150020.SGD","BK4112","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636586103","title":"BioCryst director Amy E. McKee sells 11,180 shares worth $100,284.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2636586103","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636586103?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:08","pubTimestamp":1779221303,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals: Director Amy E. McKee sold 11,180 common shares on May 18, 2026.The shares were sold at a weighted average price of USD 8.97.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL3Zpgz4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioCryst director Amy E. McKee sells 11,180 shares worth $100,284.6","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCRX","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037292","title":"BioCryst Chief Legal Officer Alane P. Barnes sells 62,500 shares for $596,250","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037292","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037292?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:14","pubTimestamp":1778876073,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals Chief Legal Officer Alane P. Barnes exercised employee stock options for 62,500 shares at USD 5.04 on May 13, 2026.Barnes sold 62,500 shares at USD 9.54 in same session.Directly owned stake fell to 400,703 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL8xfxTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioCryst Chief Legal Officer Alane P. Barnes sells 62,500 shares for $596,250","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633127741","title":"These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2633127741","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633127741?lang=en_us&edition=fundamental","pubTime":"2026-05-08 01:46","pubTimestamp":1778175972,"startTime":"0","endTime":"0","summary":"BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/05/52381286/these-analysts-revise-their-forecasts-on-biocryst-pharma-after-q1-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCRX","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633155366","title":"BioCryst Pharmaceuticals Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2633155366","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633155366?lang=en_us&edition=fundamental","pubTime":"2026-05-07 02:29","pubTimestamp":1778092140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 06, 2026 14:29 ET (18:29 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BCRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633136448","title":"BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber","url":"https://stock-news.laohu8.com/highlight/detail?id=2633136448","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633136448?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:24","pubTimestamp":1778073888,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, CVS, UberWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL6N41J0N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMDS","ANET","BCRX","NVII","PODD","COR","MASS","INGM","AMCR","ORKA","LINT","NVDY","OXY","APO","LCID","UTHR","AVTX","NVAX","RSI","COTY","ELAN","AMD","RXRX","LUMN","XOM","COP","SMCI","NYT","DECK","ARM","NVDA","DIS","OSCR","UBER","SMCL","KHC","CVX","SMCY","FRPT","CVS","MNKD","NVDQ","QCOM","ETR","GLW","CMI","OSCG","INTC","HUT","NVDB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176521691","title":"Stock Track | BioCryst Pharmaceuticals Plunges 6.98% Pre-Market on Surprise Quarterly Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1176521691","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176521691?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:48","pubTimestamp":1778071702,"startTime":"0","endTime":"0","summary":"Biocryst Pharmaceuticals (BCRX) stock experienced a pre-market plunge of 6.98% on Wednesday, following the release of its first-quarter 2026 financial results.The sharp decline is attributed to the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633187242","title":"Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q1 Net Loss $2.98 a Share, vs. FactSet Est of $0.04 EPS","url":"https://stock-news.laohu8.com/highlight/detail?id=2633187242","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633187242?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:30","pubTimestamp":1778067041,"startTime":"0","endTime":"0","summary":"Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q1 Net Loss $2.98 a Share, vs. FactSet Est of $0.04 EPS","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633182710","title":"BioCryst Pharma Q1 Adj. EPS $0.14 Beats $0.05 Estimate, Sales $156.413M Beat $151.123M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633182710","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633182710?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:15","pubTimestamp":1778066133,"startTime":"0","endTime":"0","summary":"BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.05 by 180 percent.  The company reported quarterly sales of $156.413 million which beat the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52316296/biocryst-pharma-q1-adj-eps-0-14-beats-0-05-estimate-sales-156-413m-beat-151-123m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","BK4139","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633231182","title":"BioCryst Q1 operating loss widens to $701.6 million; ORLADEYO revenue rises 11% to $148.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633231182","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633231182?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:13","pubTimestamp":1778066011,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals posted a Q1 operating loss of USD 701.6 million, swinging from operating income, on a USD 697.8 million non-cash acquired in-process R&D charge tied to the Astria acquisition.Net loss widened to USD 721.8 million, while ORLADEYO revenue rose 11% year over year to USD 148.3 million.Cash, cash equivalents, restricted cash and investments totaled USD 260.8 million at March 31; pro-forma cash climbed to USD 330.8 million including USD 70 million in net proceeds from licensing European navenibart rights after quarter end.Patient enrollment in ALPHA-ORBIT, pivotal navenibart study in hereditary angioedema, remains on track to complete by end of June, supporting a planned US regulatory filing by end of 2027.Full-year outlook was maintained, with expected 2026 global net ORLADEYO revenue of USD 625 million to USD 645 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL7kNS7F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00BN0W2T93.GBP","BK4547","LU2210150020.SGD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4139","IE00B64PRP62.GBP","BK4112","SG9999014005.SGD","BK4588","LU2095319765.USD","BCRX","NDAQ","SG9999014039.USD","BK4585","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633242184","title":"BRIEF-BioCryst Pharmaceuticals Q1 EPS USD -2.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2633242184","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633242184?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:00","pubTimestamp":1778065249,"startTime":"0","endTime":"0","summary":"BRIEF-BioCryst Pharmaceuticals Q1 EPS USD -2.98\n\n\nMay 06 (Reuters) - BioCryst Pharmaceuticals Q1 product sales USD 3.016 million.\n\nQ1 operating expenses USD 858.011 million\nQ1 net income USD -721.812 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXD17502:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4139","BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925182","title":"BioCryst Pharmaceuticals Inc - Maintains FY2026 Non-Gaap Operating Expense Guidance $450 Mln-$470 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925182","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925182?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:00","pubTimestamp":1778065204,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXD17502:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BK4139","BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633423184","title":"BioCryst Pharmaceuticals Q1 Operating Expenses USD 858.011 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633423184","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633423184?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:00","pubTimestamp":1778065204,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nPLXD17502:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCRX","BK4547","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocryst.com","stockEarnings":[{"period":"1week","weight":0.1057},{"period":"1month","weight":0.0899},{"period":"3month","weight":0.0654},{"period":"6month","weight":0.3028},{"period":"1year","weight":0.029},{"period":"ytd","weight":0.2744}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.02531},{"month":2,"riseRate":0.53125,"avgChangeRate":-0.000169},{"month":3,"riseRate":0.375,"avgChangeRate":0.017253},{"month":4,"riseRate":0.545455,"avgChangeRate":0.046266},{"month":5,"riseRate":0.545455,"avgChangeRate":0.060211},{"month":6,"riseRate":0.606061,"avgChangeRate":0.029873},{"month":7,"riseRate":0.5625,"avgChangeRate":0.113207},{"month":8,"riseRate":0.59375,"avgChangeRate":0.099672},{"month":9,"riseRate":0.34375,"avgChangeRate":-0.049493},{"month":10,"riseRate":0.5,"avgChangeRate":-0.046955},{"month":11,"riseRate":0.46875,"avgChangeRate":0.037572},{"month":12,"riseRate":0.5,"avgChangeRate":0.004698}],"exchange":"NASDAQ","name":"Biocryst Pharmaceuticals","nameEN":"Biocryst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biocryst Pharmaceuticals(BCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biocryst Pharmaceuticals,BCRX,Biocryst Pharmaceuticals股票,Biocryst Pharmaceuticals股票老虎,Biocryst Pharmaceuticals股票老虎国际,Biocryst Pharmaceuticals行情,Biocryst Pharmaceuticals股票行情,Biocryst Pharmaceuticals股价,Biocryst Pharmaceuticals股市,Biocryst Pharmaceuticals股票价格,Biocryst Pharmaceuticals股票交易,Biocryst Pharmaceuticals股票购买,Biocryst Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biocryst Pharmaceuticals(BCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}